Format

Send to

Choose Destination
Cell Metab. 2014 Nov 4;20(5):827-839. doi: 10.1016/j.cmet.2014.08.011. Epub 2014 Oct 2.

Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans.

Author information

1
Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada.
2
Department of Medicine, Laval University, IUCPQ Research Centre, Pulmonary Hypertension Research Group, Quebec, QC G1V 4G5, Canada.
3
Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada. Electronic address: em2@ualberta.ca.

Abstract

Suppression of mitochondrial function promoting proliferation and apoptosis suppression has been described in the pulmonary arteries and extrapulmonary tissues in pulmonary arterial hypertension (PAH), but the cause of this metabolic remodeling is unknown. Mice lacking sirtuin 3 (SIRT3), a mitochondrial deacetylase, have increased acetylation and inhibition of many mitochondrial enzymes and complexes, suppressing mitochondrial function. Sirt3KO mice develop spontaneous PAH, exhibiting previously described molecular features of PAH pulmonary artery smooth muscle cells (PASMC). In human PAH PASMC and rats with PAH, SIRT3 is downregulated, and its normalization with adenovirus gene therapy reverses the disease phenotype. A loss-of-function SIRT3 polymorphism, linked to metabolic syndrome, is associated with PAH in an unbiased cohort of 162 patients and controls. If confirmed in large patient cohorts, these findings may facilitate biomarker and therapeutic discovery programs in PAH.

PMID:
25284742
DOI:
10.1016/j.cmet.2014.08.011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center